ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Explore linked clinical trials.9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Depressive Disorder, Treatment-Resistant, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-10-05 | NCT07284667 | |
| ACP-204 in Adults With Alzheimer's Disease Psychosis | Hallucinations, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, perceptual disorders | Recruiting | Phase 2 / Phase 3 | 2026-10-05 | NCT06159673 | |
| Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis | Lewy Body Dementia Psychosis | Recruiting | Phase 3 | 2026-09-29 | NCT07095465 | |
| Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis | Lewy Body Dementia Psychosis | Recruiting | Phase 2 | 2026-09-29 | NCT07029581 | |
| Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder | autism, autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-02 | NCT05999240 | |
| Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 4 | 2026-08-07 | NCT05357612 | |
| ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study | Hallucinations, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, perceptual disorders | Enrolling by invitation | Phase 3 | 2026-08-05 | NCT06194799 | |
| Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | Hyperphagia in Prader-Willi Syndrome | Active, not recruiting | Phase 3 | 2025-09-10 | NCT06173531 | |
| Pimavanserin and Aggression and Social Cognition. | Disruptive, Impulse Control, and Conduct Disorders, intermittent explosive disorder, psychiatric disorder | Recruiting | Phase 2 | 2025-03-27 | NCT05895513 |